Jennifer L Goldman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/779507/publications.pdf

Version: 2024-02-01

58 papers 948 citations

16 h-index 28 g-index

61 all docs

61 docs citations

61 times ranked

1264 citing authors

#	Article	IF	CITATIONS
1	Urban Classification, Not COVID-19 Community Rates, Was Associated With Modes of Learning in US K–12 Schools?. Pediatrics, 2022, 149, .	1.0	6
2	Inpatient outcomes for children receiving empiric methicillinâ€resistant Staphylococcus aureus coverage for complicated pneumonia. Journal of Hospital Medicine, 2022, 17, 36-41.	0.7	2
3	HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure. Pharmacogenomics Journal, 2022, 22, 124-129.	0.9	5
4	Simultaneous Quantification of Trimethoprim Metabolites in Pediatric Plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1198, 123232.	1.2	0
5	Novel outpatient antibiotic prescribing report of respiratory infections in a pediatric health system's emergency departments and urgent care clinics. American Journal of Infection Control, 2021, 49, 398-400.	1.1	10
6	Enhancing Pediatric Adverse Drug Reaction Documentation in the Electronic Medical Record. Journal of Clinical Pharmacology, 2021, 61, 181-186.	1.0	9
7	Utilization of the Naranjo scale to evaluate adverse drug reactions at a free-standing children's hospital. PLoS ONE, 2021, 16, e0245368.	1.1	13
8	Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity. Clinical Pharmacology and Therapeutics, 2021, 109, 905-917.	2.3	7
9	Trimethoprim–Sulfamethoxazole–associated Fulminant Respiratory Failure in Children and Young Adults. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 918-921.	2.5	4
10	Perceived Harm May Be Helpful: Fear of Fluoroquinolone-Associated Adverse Events in Children. Pediatrics, 2021, 147, .	1.0	2
11	Precision dosing of vancomycin: in defence of AUC-guided therapy in children. Journal of Antimicrobial Chemotherapy, 2021, 76, 2494-2497.	1.3	3
12	Risks and mitigation strategies to prevent etoposide infusionâ€related reactions in children. Pharmacotherapy, 2021, 41, 700-706.	1.2	5
13	Evaluating and Mitigating Risk of Acute Kidney Injury with the Combination of Vancomycin and Piperacillin-Tazobactam in Children. Paediatric Drugs, 2021, 23, 373-380.	1.3	3
14	Methods for Detecting Pediatric Adverse Drug Reactions From the Electronic Medical Record. Journal of Clinical Pharmacology, 2021, 61, 1479-1484.	1.0	2
15	Severe cutaneous adverse reactions: comparing outcomes in children with and without complex chronic conditions. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 790-792.e3.	2.0	O
16	A Moving Targetâ€"Vancomycin Therapeutic Monitoring. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 474-478.	0.6	16
17	Screening trimethoprim primary metabolites for covalent binding to albumin. Medicinal Chemistry Research, 2020, 29, 1238-1246.	1.1	6
18	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.0	41

#	Article	IF	Citations
19	Implementation of a nurse-driven antibiotic engagement tool in 3 hospitals. American Journal of Infection Control, 2020, 48, 1415-1421.	1.1	10
20	Nurses as antimicrobial stewards: Recognition, confidence, and organizational factors across nine hospitals. American Journal of Infection Control, 2020, 48, 239-245.	1.1	14
21	Pediatric SJS-TEN: Where are we now?. F1000Research, 2020, 9, 982.	0.8	20
22	A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 244-250.e1.	2.0	19
23	Cost and Potential Avoidability of Antibiotic-Associated Adverse Drug Reactions in Children. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 66-68.	0.6	15
24	Characterization of Severe Adverse Drug Reactions at a Freeâ€Standing Children's Hospital. Journal of Clinical Pharmacology, 2019, 59, 1569-1572.	1.0	7
25	Clinical impact of an antimicrobial stewardship program on high-risk pediatric patients. Infection Control and Hospital Epidemiology, 2019, 40, 968-973.	1.0	12
26	Severe Acute Respiratory Failure in Healthy Adolescents Exposed to Trimethoprim-Sulfamethoxazole. Pediatrics, 2019, 143, .	1.0	10
27	Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. European Journal of Clinical Pharmacology, 2019, 75, 1135-1141.	0.8	16
28	To Discharge or Not to Discharge on Outpatient Parenteral Antimicrobial Therapy: That Is the Question. Hospital Pediatrics, 2019, 9, 314-316.	0.6	5
29	An electronic medical records-based approach to identify idiosyncratic drug-induced liver injury in children. Scientific Reports, 2019, 9, 18090.	1.6	7
30	Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatric Nephrology, 2019, 34, 261-267.	0.9	29
31	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	2.0	134
32	Incidence, outcomes, and resource use in children with Stevensâ€Johnson syndrome and toxic epidermal necrolysis. Pediatric Dermatology, 2018, 35, 182-187.	0.5	40
33	Integrating staff nurses in antibiotic stewardship: Opportunities and barriers. American Journal of Infection Control, 2018, 46, 737-742.	1.1	45
34	Variability of surgical prophylaxis in penicillin-allergic children. Infection Control and Hospital Epidemiology, 2018, 39, 1480-1483.	1.0	11
35	Trimethoprim: The overlooked component of trimethoprimâ€sulfamethoxazole idiosyncratic adverse drug reactions. Pharmacoepidemiology and Drug Safety, 2018, 27, 949-951.	0.9	5
36	Pharmacology of Mycobacterial Drugs in Children. Journal of Pediatric Infectious Diseases, 2018, 13, 101-112.	0.1	0

#	Article	IF	Citations
37	Pharmacokinetics of Clindamycin in Obese and Nonobese Children. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	33
38	Clinical Impact of an Antibiotic Stewardship Program at a Children's Hospital. Infectious Diseases and Therapy, 2017, 6, 103-113.	1.8	20
39	Extending Antimicrobial Stewardship to All Hospitalized Children: The Time Is Now. Hospital Pediatrics, 2017, 7, 559-561.	0.6	2
40	Staff nurses as antimicrobial stewards: An integrative literature review. American Journal of Infection Control, 2017, 45, 917-922.	1.1	41
41	Clinical Impact of Two Different Multiplex Respiratory Panel Assays on Management of Hospitalized Children Aged â‰ 2 4Âmonths. Open Forum Infectious Diseases, 2017, 4, S32-S33.	0.4	1
42	Costs of Antimicrobial Stewardship Programs at US Children's Hospitals. Infection Control and Hospital Epidemiology, 2016, 37, 852-854.	1.0	12
43	Safety Concerns Surrounding Quinolone Use in Children. Journal of Clinical Pharmacology, 2016, 56, 1060-1075.	1.0	74
44	Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes. Drug Metabolism and Disposition, 2016, 44, 1603-1607.	1.7	13
45	Clinical variables and Staphylococcus aureus virulence factors associated with venous thromboembolism in children. Thrombosis Research, 2016, 138, 69-73.	0.8	13
46	Infections Are Associated with Higher Risk of Venous Thromboembolism in Hospitalized Children with Nephrotic Syndrome. Blood, 2016, 128, 3811-3811.	0.6	0
47	Clinical Diagnoses and Antimicrobials Predictive of Pediatric Antimicrobial Stewardship Recommendations: A Program Evaluation. Infection Control and Hospital Epidemiology, 2015, 36, 673-680.	1.0	22
48	Tip of the Iceberg: Understanding the Unintended Consequences of Antibiotics. Pediatrics, 2015, 136, e492-e493.	1.0	7
49	Editorial Commentary:Pediatric Acute Kidney Injury: Is the Addition of Gentamicin Worth the Risk?. Clinical Infectious Diseases, 2015, 61, 1125-1126.	2.9	1
50	New Horizons for Pediatric Antibiotic Stewardship. Infectious Disease Clinics of North America, 2015, 29, 503-511.	1.9	15
51	In Vitro Hepatic Oxidative Biotransformation of Trimethoprim. Drug Metabolism and Disposition, 2015, 43, 1372-1380.	1.7	23
52	Clinical Impact of an Antimicrobial Stewardship Program on Pediatric Hospitalist Practice, a 5-Year Retrospective Analysis. Hospital Pediatrics, 2015, 5, 520-527.	0.6	22
53	Urinary Biomarkers of Trimethoprim Bioactivation in Vivo Following Therapeutic Dosing in Children. Chemical Research in Toxicology, 2014, 27, 211-218.	1.7	10
54	No Evidence of Vancomycin Minimal Inhibitory Concentration Creep or Heteroresistance Identified in Pediatric Staphylococcus aureus Blood Isolates. Pediatric Infectious Disease Journal, 2014, 33, 216-218.	1.1	21

#	Article	IF	CITATIONS
55	Trends in Adverse Reactions to Trimethoprim-Sulfamethoxazole. Pediatrics, 2013, 131, e103-e108.	1.0	17
56	Pediatric Pharmacovigilance: Enhancing Adverse Drug Reaction Reporting in a Tertiary Care Children's Hospital. Therapeutic Innovation and Regulatory Science, 2013, 47, 566-571.	0.8	14
57	Picture of the Month—Quiz Case. JAMA Pediatrics, 2012, 166, 185.	3.6	3
58	Development of biomarkers to optimize pediatric patient management: what makes children different?. Biomarkers in Medicine, 2011, 5, 781-794.	0.6	49